Patients with COVID-19 in the Intensive Care Unit (ICU) or hospitalized with severe form have a poor prognosis (almost 30% rate of death). They present often a high cardiovascular risk profile (almost 30% of hypertension and 19% of diabetes). Troponin has been described to be elevated in a high proportion of patients (one fifth of all patients and 50% of non-survivors) suggesting the possibility of cardiomyopathies. High levels of DDimers (81% of non survivors) and fibrin degradation products are also associated with increased risk of mortality suggesting also the possibility of venous thromboembolism. Therefore, screening for cardiomyopathies and venous thromboembolism could represent an important challenge for patients with COVID-19 management.
Study Type
OBSERVATIONAL
Enrollment
198
Centre Hospitalier de Cannes
Cannes, France
CHU de Dijon
Dijon, France
Centre Hospitalier de Draguignan
Draguignan, France
Centre Hospitalier de Grasse
Grasse, France
Clinique Ambroise-Paré
Neuilly, France
CHU de Nice
Nice, France
Hôpitaux Universitaires Paris Centre - Hôpital Cochin
Paris, France
CHU de REIMS
Reims, France
Determine the incidence of cardiomyopathies and venous thromboembolism
Incidence of cardiomyopathies and/or venous thromboembolism at day 28
Time frame: 28 days
Mortality
Incidence of mortality at day 28
Time frame: 28 days
Duration of mechanical ventilation
Number of day of using mechanical ventilation for each patients
Time frame: hospitalisation duration
Shock
Incidence of shock during hospitalisation
Time frame: hospitalisation duration
length of stay
Number of day at hospital
Time frame: hospitalisation duration
Mechanical ventilation
Setting up or not of mechanical ventilation
Time frame: hospitalisation duration
Renal replacement therapy
Administration or not of renal replacement therapy
Time frame: hospitalisation duration
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.